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effectiveness literature. METHODS: A literature search was con-
ducted in MEDLINE to identify the published articles on HF
from 1993 to 2007 with a focus on economic evaluations and
resource use. Six review articles were found which summarized
31 economic studies for ACE inhibitors, beta-blockers and
digoxin through 2004. None of the review articles had summa-
rized the studies for ARBs, aldosterone receptor blockers, or
evidence from real-world studies. RESULTS: After excluding
studies summarized in the previous review papers, we found 29
new economic analyses for drugs used to treat HF. Among these,
22 studies were based on data available from clinical trials. These
included 14 cost-effectiveness analyses (CEA), 1 CEA/cost-utility
analysis, 1 CEA/cost-consequence analysis, 4 CEA/cost-beneﬁt
analyses (CBA), 1 CBA and 1 budget impact analysis. The
remaining analyses were studies conducted using real-world
data. Five studies compared ARBs to placebos or ACE inhibitors,
out of which four suggested cost-savings or cost-effectiveness for
ARBs, and one showed higher costs for ARBs. For the remaining
drugs, evidence that treatment was cost-saving was observed in
16 studies and that the treatment had favorable cost-effectiveness
ratio was observed in 7 studies. Finally, one study comparing
costs among beta-blockers found bisoprolol to be the most cost-
effective drug. CONCLUSION: Economic studies analyzing
drugs used to treat HF can help in making rational decisions
regarding provision of care. However, there is need of more
comparative economic studies between same class drugs to
inform prescription drug decisions.
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OBJECTIVE: Evidence demonstrates a strong association
between reductions in LDL-C achieved with statin therapy and
reductions in cardiovascular events. Several cost-effectiveness
analyses have incorporated LDL-C reduction, which is a “surro-
gate endpoint”, as indicator for effectiveness of interventions in
their models. Interpretations of cost-effectiveness analyses with
surrogate endpoints may confuse decision-makers. Therefore,
clinically important endpoints (hard endpoints) such as cardio-
vascular events may be a better alternative to comprehend the
magnitude of the cost-effectiveness of therapeutics. The objective
is to estimate cost savings through cardiovascular event reduction
correlated with LDL-C reduction in patients with hypercholester-
olemia on statin therapy using pragmatic head-to-head RCTs
from a Canadian perspective. METHODS: Reducing LDL-C was
incorporated into an economic analysis through a reduction in
cardiovascular (cardiac and cerebrovascular) events. Data for
LDL-C reduction from a head-to-head RCT [Am Heart J
2002;144:1036–43]; rosuvastatin (starting 5 mg) versus simvas-
tatin (starting 20 mg) with up-titration doses; and distribution of
cardiovascular risk for users [N = 100,000, 5 years] in Canadian
population [Clin Invest Med 2007;30:E63–E69]. Medical costs
are from the perspective of the Canadian health care system.
RESULTS: It is estimated that approximate acquisition costs for
simvastatin is more than $14 million less than acquisition costs
for rosuvastatin. Health care cost-savings through cardiovas-
cular events prevention related to statin therapy are estimated
as follows: Non-fatal myocardial infarction, rosuvastatin
($97,488,572) and simvastatin ($88,086,070); ischemic stroke,
rosuvastatin ($63,178,674)and simvastatin ($57,085,510). Rosu-
vastatin saves almost $15.5 (95%CI: $14.8, $16.2) million com-
pared to simvastatin due to cardiovascular events reduction.
Rosuvastatin and simvastatin can prevent 3161 and 2857 deaths,
respectively. CONCLUSION: Although the acquisition cost for
simvastatin is much less than that for rosuvastatin, the economic
beneﬁts of dyslipidemia management with rosuvastatin in the
Canadian population is estimated to be signiﬁcantly superior to
simvastatin therapy through a reduction in costs associated with
the management of cardiovascular events and sequelae.
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OBJECTIVE: To assess the cost-effectiveness of LDL cholesterol
reduction based upon the 2004 NCEP guideline update for ator-
vastatin, lovastatin, rosuvastatin, simvastatin, atorvastatin plus
ezetimibe, lovastatin plus extended-release niacin, and simva-
statin plus ezetimibe from a third-party payer’s perspective.
METHODS: Literature-based decision analyses were conducted
to evaluate direct costs, treatment outcomes deﬁned as LDL goals
of <70 and <100 mg/dl, and clinically-signiﬁcant adverse events.
Each of the decision trees consisted of four initial monotherapy
treatment arms and also considered combination therapy versus
dose titration if treatment goals were not achieved. Base cases
were deﬁned according to NCEP high-risk patient classiﬁcations
and ﬁve categories of baseline LDL levels from the 1999–2002
National Health and Nutrition Examination Survey (NHANES).
Meta-analyses were performed to estimate percent LDL reduc-
tions for each agent and for each dose. Monte Carlo simulations
and probabilistic sensitivity analyses were used to yield incre-
mental cost-effectiveness ratios, conﬁdence intervals, and graphi-
cal representations of ﬁndings. One-way sensitivity analyses were
conducted on key variables of uncertainty and costs. RESULTS:
Overall, costs were observed to higher and effectiveness lower
among patients seeking a <70 mg/dl goal. Simvastatin was found
to be the most cost-effective treatment option for both
<70 mg/dL and <100 mg/dl goals and for each baseline LDL
cholesterol strata. Combination therapy was more cost-effective
compared to dose titration among the <70 mg/dl goal and in
those requiring LDL reductions above 45%. Analyses indicated
that the recent generic pricing of simvastatin substantially
impacted results. CONCLUSION: From a third-party payer per-
spective and among high-risk patients, simvastatin (including
monotherapy and combination with ezetimibe), was observed to
be the most cost-effective treatment option for LDL treatment
goals of <70 and <100 mg/dl. Further research is warranted
concerning combination therapies and in evaluating additional
surrogate outcomes such as high-density lipoprotein (HDL).
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OBJECTIVE: The REACH Registry shows that the rate of death,
myocardial infarctions (MI) and ischaemic strokes (IS) increase
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